3-((2-methyl-2-(2-methyl-5-nitrobenzyl)hydrazono)methyl)pyrazolo[1,5-a]pyridine-5-carbonitrile | 1101119-63-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 英文名称: 3-((2-methyl-2-(2-methyl-5-nitrobenzyl)hydrazono)methyl)pyrazolo[1,5-a]pyridine-5-carbonitrile
• 英文别名: 3-[[Methyl-[(2-methyl-5-nitrophenyl)methyl]hydrazinylidene]methyl]pyrazolo[1,5-a]pyridine-5-carbonitrile
• CAS: 1101119-63-4
• 化学式: C₁₈H₁₆N₆O₂
• 分子量: 348.364
• InChiKey: LVYPYQZOGVQVDW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  103
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  吡唑并[1,5-a]吡啶-5-羧酸 在 N,N'-羰基二咪唑 、 三氯氧磷 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 111.5h， 生成 3-((2-methyl-2-(2-methyl-5-nitrobenzyl)hydrazono)methyl)pyrazolo[1,5-a]pyridine-5-carbonitrile
  参考文献：
  名称：

  [EN] PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY
  [FR] PYRAZOLO[1,5-A]PYRIDINES ET LEUR UTILISATION EN CANCÉROTHÉRAPIE

  摘要：

  Pyrazolo[1,5-a]吡啶类化合物被描述，包括它们的制备方法，以及它们作为抗癌治疗药物或药剂的用途，无论是单独使用还是与放疗和/或其他抗癌药物联合使用。

  公开号：

  WO2009008748A1

文献信息

• Novel pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors: Exploring the benzenesulfonohydrazide SAR
  作者：Jackie D. Kendall、Anna C. Giddens、Kit Yee Tsang、Raphaël Frédérick、Elaine S. Marshall、Ripudaman Singh、Claire L. Lill、Woo-Jeong Lee、Sharada Kolekar、Mindy Chao、Alisha Malik、Shuqiao Yu、Claire Chaussade、Christina Buchanan、Gordon W. Rewcastle、Bruce C. Baguley、Jack U. Flanagan、Stephen M.F. Jamieson、William A. Denny、Peter R. Shepherd

  DOI：10.1016/j.bmc.2011.11.031

  日期：2012.1

  Structure-activity relationship studies of the pyrazolo[1,5-a]pyridine class of PI3 kinase inhibitors show that substitution off the hydrazone nitrogen and replacement of the sulfonyl both gave a loss of p110 alpha selectivity, with the exception of an N-hydroxyethyl analogue. Limited substitutions were tolerated around the phenyl ring; in particular the 2,5-substitution pattern was important for PI3 kinase activity. The N-hydroxyethyl compound also showed good inhibition of cell proliferation and inhibition of phosphorylation of Akt/PKB, a downstream marker of PI3 kinase activity. It had suitable pharmacokinetics for evaluation in vivo, and showed tumour growth inhibition in two human tumour cell lines in xenograft studies. This work has provided suggestions for the design of more soluble analogues. (C) 2011 Elsevier Ltd. All rights reserved.
• [EN] PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY<br/>[FR] PYRAZOLO[1,5-A]PYRIDINES ET LEUR UTILISATION EN CANCÉROTHÉRAPIE
  申请人：AUCKLAND UNISERVICES LTD

  公开号：WO2009008748A1

  公开（公告）日：2009-01-15

  Pyrazolo[1,5-a]pyridines are described, including methods for their preparation, and their use as agents or drugs for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.

  Pyrazolo[1,5-a]吡啶类化合物被描述，包括它们的制备方法，以及它们作为抗癌治疗药物或药剂的用途，无论是单独使用还是与放疗和/或其他抗癌药物联合使用。